Impact of Human Papillomavirus Carriage on IVF/ICSI Results (HPV AMP)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age25-38
SponsorUniversity Hospital, Brest
About this trial
The prevalence of the papilloma virus in the general population is 12%. This virus is known to impair male fertility but its impact on female infertility remains uncertain. This is a public health problem since there is a vaccination protocol. Demonstrating the impact of the human papillomavirus on fertility would be an argument in favor of vaccination.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
all etiology of infertility AMH > ou = à 1.1 ng/ml First ou second protocol of IVF between 25 years and 37 years and 11 months
Disqualifiers
None
Trial population
The population study is a population of infertile women who are consulting in our center of Reproduction Médicine in CHU Brest.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
clinical pregnancy rate after fresh eSET by HPV status
A clinical pregancy is the visualisation of a gestational sac inside the uterus after 6 weeks of gestation
Time frame
1 yearSecondary outcomes
1
IVF issues
oocytes number, embryos number, fecondation rate, implantation rate
Time frame
1 year2
Positive HPV rate
number of women who have a positive HPV test before IVF procedure
Time frame
1 yearSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov